Loss of hearing is a rare complication of chronic myeloid leukaemia.' 2 We describe the occurrence of varying degrees of impairment of hearing in nine out of 44 Nigerian patients with the disease.
Patients, methods, and results
Chronic myeloid leukaemia was diagnosed in the usual way based on clinical and laboratory findings including total and differential white cell counts. Cytogenetic analysis was not routinely available. The diagnosis of hearing disorders was based on the history given by the patient as well as on findings of routine physical examination. In addition, audiometric studies were performed when indicated, and these were repeated at intervals when possible. In order to evaluate the influence of anaemia and severity of hyperleucocytosis at the time of occurrence of hearing impairment, each patient with an auditory complication of chronic myeloid leukaemia was matched according to age, sex, and state of the disease-that is, whether in a "steady" or accelerated phase-with control patients suffering from the disease but who did not have clinical evidence of a hearing problem. Relevant laboratory data were compared by the usual statistical methods.
Eight of the nine patients with auditory problems were clinically and haematologically in the chronic phase of their disease at the time that the problem occurred. Comparison of the packed cell volumes and white cell counits of these patients (table) with those of the controls showed no significant difference in median packed cell volumes (0-24 v 0 33; p >0 05) but a significantly higher median white cell count in the group with impaired hearing (434 Ox 109/1 v 257-Ox 10' 1; p<0 05). Three of the five patients with moderate hearing impairment who were followed up long enough during chemotherapy showed a remarkable subjective improvement in hearing associated with a reduction in the peripheral white cell count to the range 10 0-20 0x 1091; in the remaining four patients, however (cases 2, 5, 6, 7), profound deafness persisted despite similar satisfactory haematological control.
Comment
We have described auditory disturbances ranging in severity from mild to profound loss of hearing occurring in nine of 44 Nigerian patients with chronic myeloid leukaemia who presented either at an advanced stage or after prolonged lack of control of the disease.
It appears most likely that the uniformly associated high degree of leucocytosis (table) is a major predisposing factor in the pathogenesis of this complication. The role of severe anaemia, which was present in six of our patients (table), is less clear. Hyperleucocytosis may lead to the formation of leucocyte thrombi and failure of the microvasculature,3 which for unknown reasons manifested in our patients as auditory impairment and also as cerebellar ataxia (case 2), priapism (case 4), and "organic brain syndrome" (case 7). The central role of the physical characteristics of the leucocytes4 concerned in the leucostasis is underscored by the fact that none of 34 patients with chronic lymphocytic leukaemia who had white cell counts in the same range as our nine patients with chronic myeloid leukaemia manifested any signs of leucostatic syndromes.
Although chronic myeloid leukaemia is largely incurable-, its effective control with chemotherapy usually ensures a reasonably good quality of life for about three to five years in most cases.' 2 Owing to socioeconomic and, in some cases, cultural factors Nigerian patients with chronic myeloid leukaemia present at very late stages of their disease; and often are unable to receive regular chemotherapy. Of all the disabilities suffered consequently, loss of hearing appears to be the most distressing to the patient: early diagnosis and effective control of the disease, as in many developed countries, should reduce its occurrence in the future among Nigerians.
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British patients with haemophilia, like Americans, have been exposed to HTLV-Ill for at least four years.4 Most of our seropositive patients had had large amounts of factor VIII treatment, predominantly commercial concentrate from the United States, often over 50 000 units/year of factor VIII activity. Four patients who seroconverted during 1984, however, had had little treatment, including one man who had used only 3250 units during 1983, all from the same batch of commercial concentrate. Five patients had used only products from the National Health Service over five years, and all were seronegative, in keeping with the low prevalence of anti-HTLV-III in British blood donors. ' To what extent should we inform these patients about their antibody state without causing anxiety? For example, four patients who were seropositive for four years had normal T4 lymphocyte counts and would probably not develop AIDS, although recently detected lymphadenopathy and splenomegaly in one suggests caution. Lymphadenopathy and splenomegaly in patients with haemophilia, however, may have causes other than AIDS. Unfortunately we failed to identify features that might help distinguish between self limiting HTLV-III infection and infection leading to AIDS or a carrier state. Urgency is underlined by the recent report of transmission of AIDS from a patient with haemophilia to his child via his spouse.5 A genetic or additional acquired factor may be proved necessary for the development of AIDS from HTLV-III infection. Until then, patients with haemophilia who are seronegative from exposure to the virus must be protected and those who have already been infected monitored.
